Risk factors associated with fatal influenza, Romania, October 2009 – May 2011

Laurentiu Zolotusca,a Pernille Jorgensen,b Odette Popovici,c Adriana Pistol,c Florin Popovici,c Marc-Alain Widdowson,d Viorel Alexandrescu,e Alina Ivanciuc,e Po-Yung Cheng,d Diane Gross,d Caroline S. Brown,b Joshua A. Mott

aMinistry of Health, Bucharest, Romania. bWHO Regional Office for Europe, Copenhagen, Denmark. cNational Institute of Public Health, Bucharest, Romania. dInfluenza Division, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA. eCantacuzino Institute on Research and Development on Microbiology and Immunology, Bucharest, Romania.

Correspondence: Joshua A. Mott, Influenza Program Director, Centers for Disease Control and Prevention- Kenya, KEMRI Headquarters, Mbagathi Rd. off Mbagathi Way, P.O. Box 606, Village Market 00621, Nairobi, Kenya. E-mail: jmott@kc.cdc.gov

Accepted 26 September 2013. Published Online 20 November 2013.

Background Limited data are available from Central and Eastern Europe on risk factors for severe complications of influenza. Such data are essential to prioritize prevention and treatment resources and to adapt influenza vaccination recommendations.

Objectives To use sentinel surveillance data to identify risk factors for fatal outcomes among hospitalized patients with severe acute respiratory infections (SARI) and among hospitalized patients with laboratory-confirmed influenza.

Methods Retrospective analysis of case-based surveillance data collected from sentinel hospitals in Romania during the 2009/2010 and 2010/2011 winter influenza seasons was performed to evaluate risk factors for fatal outcomes using multivariate logistic regression.

Results During 2009/2010 and 2010/2011, sentinel hospitals reported 661 SARI patients of which 230 (35%) tested positive for influenza. In the multivariate analyses, infection with influenza A(H1N1)pdm09 was the strongest risk factor for death among hospitalized SARI patients (OR: 6.6; 95% CI: 3.3–13.1). Among patients positive for influenza A(H1N1)pdm09 virus infection (n = 148), being pregnant (OR: 7.1; 95% CI: 1.6–31.2), clinically obese (OR: 2.9; 95% CI: 1.6–31.2), and having an immunocompromising condition (OR: 3.7; 95% CI: 1.1–13.4) were significantly associated with fatal outcomes.

Conclusion These findings are consistent with several other investigations of risk factors associated with influenza A(H1N1) pdm09 virus infections. They also support the more recent 2012 recommendations by the WHO Strategic Advisory Group of Experts on Immunization (SAGE) that pregnant women are an important risk group for influenza vaccination. Ongoing sentinel surveillance can be useful tool to monitor risk factors for complications of influenza virus infections during each influenza season, and pandemics as well.

Keywords Influenza, risk factors, Romania, severe acute respiratory illness, surveillance.
reporting to the county health authority. The clinical case definition for SARI in persons ≥5 years of age was as follows: onset of orally measured fever >38°C, cough or sore throat, and shortness of breath or difficulty in breathing within 7 days prior to hospital admission. For children aged <5 years, the WHO Integrated Management of Childhood Illnesses clinical criteria for respiratory signs were applied.3

Epidemiological data considered in these analyses included patient date of birth (age); sex; week of hospitalization; time from onset to care-seeking; time from onset to specimen collection; signs and symptoms present on admission; pre-existing conditions (asthma, chronic pulmonary disease, cardiac disease, diabetes, immunocompromised status, hepatic disease, renal disease, and clinicians' judgement of clinical obesity); pregnancy status (reported by female patients of reproductive age); history of monovalent or trivalent influenza vaccination during the 2009/10 and 2010/11 seasons; oseltamivir use at time of case detection, and outcome (death or discharge).

Nasopharyngeal and oropharyngeal swab specimens were collected from detected SARI patients during weeks 40/2009–20/2010; and 40/2010–20/2011. Swabs were placed in a single viral transport media and sent to the Cantacuzino Institute on Research and Development 2 on Microbiology and Immunology in Bucharest, Romania for confirmatory diagnostic testing. The specimens were analyzed by rRT-PCR for influenza A(H1N1)pdm09, seasonal influenza A(H1N1) and A(H3N2), and influenza B using the WHO CDC reagent kit for influenza diagnostics.3

We conducted bivariate and multivariate logistic regression analyses to evaluate risk factors for fatal outcomes in patients hospitalized with (i) SARI and (ii) SARI that tested positive for influenza virus infections. When evaluating risk factors for fatal outcomes due to SARI, we considered laboratory-confirmed infection with influenza A(H1N1)pdm09, A(H3N2), or influenza B as independent risk factors for fatal outcomes in comparison with a reference group of influenza-negative persons. All variables associated with a fatal outcome in the bivariate analyses at a significance level of \( P < 0.05 \) were included in the multivariate model. Using backward stepwise elimination, variables that were not significantly associated (i.e., \( P > 0.05 \)) with a fatal outcome were then excluded. For all variables that were statistically significant, we evaluated their interaction with influenza infection independent of any main effects to predict a fatal outcome for SARI. All risk factor analyses were performed with Stata 10.0 (StataCorp, College Station, TX, USA).
Results

A total of 661 SARI patients were identified during the two seasons. Fifty-five percent (360/661) were male, the median age was 22 (range 0–86 years). Of 661 SARI cases, 230 (34.8%) tested positive for influenza. Of these 230 positive cases, 148 (64.3%) tested positive for A(H1N1)pdm09, 81 (35.2%) for influenza B, and 1 (0.4%) for A(H3N2) (Figure 2). Of the 148 influenza A(H1N1)pdm09 viruses, 19 (12.8%) were from SARI patients aged 0–4 years, 121 (81.8%) from patients 5–64 years, and eight (5.4%) from patients 65 years and older. The 81 influenza B patients (all from 2010/2011) included 20 (24.7%) aged 0-4, 54 (66.7%) aged 5–64, and seven (8.6%) aged 65 years and older. Of 648 SARI patients with information on influenza vaccination 11 (1.7%) reported receiving either the 2009 monovalent or the 2010/2011 trivalent influenza vaccines. The mean (median) time from symptom onset to NP/OP swab collection was 4 (4) days for both influenza-positive and influenza-negative SARI cases.

Factors associated with fatal outcomes in patients hospitalized with SARI

Of 661 SARI cases, 44 (6.7%) were fatal. Thirty-two (72.7%) of the 44 fatal SARI cases were laboratory-confirmed to have influenza virus infections [29 influenza A(H1N1)pdm09 and three influenza B] indicating the overall case-fatality percentage (CFP) of 13.9% (32 deaths/230 influenza hospitalizations). The observed CFP was 19.6% (29/148) for influenza A(H1N1)pdm09 infections and 3.7% (3/81) for influenza B infections.

In the multivariate model, there were 659 SARI cases with complete data. The single influenza A(H3N2) case was excluded from analysis. Influenza A(H1N1)pdm09 infection was strongly and independently associated with a fatal outcome. Other variables significantly and independently associated with a fatal outcome were being pregnant, having hepatic disease, increasing age in years, and increasing time from onset to hospital admission. Influenza B was not significantly associated with fatal outcomes relative to other causes of SARI hospitalizations. None of the variables displayed significant interactions with influenza A(H1N1)pdm09 infection to predict fatal outcomes from SARI.

Risk factors associated with fatal outcomes in SARI patients testing positive for influenza A(H1N1) pdm09

Analyses of risk factors for fatal outcomes among those testing positive for influenza were limited to patients testing positive for influenza A(H1N1)pdm09, as this was the only influenza type or subtype that included an analyzable sample size. In the multivariate model, pregnancy, clinical obesity, having an immunocompromising condition, and hepatic disease (P = 0.057) were independent risk factors for a fatal outcome among influenza-positive patients (Table 1).

Discussion

In Romania during 2009–2011, influenza A(H1N1)pdm09 virus infection was a strong predictor of fatal outcomes in persons with hospitalized SARI. Patients reported to be clinically obese, pregnant women, and persons with immune-compromising conditions were more likely to die from influenza than others hospitalized with influenza. These findings are consistent with other investigations of risk factors associated with influenza A(H1N1)pdm09 infections4–8 and also support the 2012 recommendations by the WHO Strategic Advisory Group of Experts on Immunization that pregnant women are an important risk group

Figure 2. SARI admissions and influenza detections by week, Romania, 2009/2010 and 2010/2011 winter influenza seasons. The data in this figure are limited to the six sentinel hospitals that operated continuously through the 2009/10 and 2010/11 winter influenza seasons.
for influenza vaccination. The percentage of SARI patients that received monovalent or trivalent influenza vaccine (1-7%) was lower than coverage rates observed in the Romanian population during the study period (2009/10 – 5.2 trivalent, 8.0% monovalent; 2010/11 – 5.6% trivalent). Thus, it is also conceivable that expanded vaccine uptake in these population subgroups could further reduce influenza-associated severe outcomes in Romania.

The CFP of 19.6% for influenza A(H1N1)pdm09 infections was higher than CFP of 7% reported in the United States or 14.3% in Australia and New Zealand. While the CFP may have been higher in Romania, other factors may also account for this finding. Only public hospitals are represented in this surveillance system, and it is unclear if the CFP would remain similar if private facilities were included. Given the voluntary nature of the surveillance and limited work-hours of hospital epidemiologists, it is also possible that a more severe proportion of admitted SARI patients were detected by participating clinicians, and this could have varied by ward or patient type. However, as no rapid diagnostic tests were in use in the sentinel hospitals, doctors would have been unaware of the influenza status of SARI patients at the time of admission or case reporting.

Other possible limitations to these findings include the requirement of measured fever in the SARI case definition. This may have limited sensitivity to detect influenza in the old and young, who may be less likely to present with fever. PCR testing may also have missed persons, particularly elderly persons, presenting with sequelae of earlier influenza infections in whom viruses could no longer be detected. Our measurement of treatment, including oseltamivir use, occurred at time of case detection and was possibly not comprehensive. We also had limited statistical power to determine whether the risk factors for fatal influenza were different from those for fatal respiratory disease in general. We also cannot yet review differences in hospital-specific mortality or look at risk for death due to subtypes of influenza other than A(H1N1)pdm09. As testing for influenza only occurred during the periods of weeks 40–20, we may have missed influenza cases outside of this time period. Finally, we did not collect information on the ethnic status of patients, so we were unable to determine whether potentially vulnerable population subgroups (e.g., the Roma population) were at higher risk of fatal outcomes.

The quality of routine surveillance data from systems relying on over-stretched clinicians to detect and report cases may be limited in comparison with data collected in targeted research programs. However, the consistency of findings from these data with other published studies on risk factors for fatal influenza supports the use of ongoing surveillance data to monitor virological trends in the epidemiology of influenza and to serve as a tool to monitor risk factors for complications of influenza virus infections during each influenza season.

**Acknowledgements**

We would like to acknowledge J. Bresee, A. Moen, S. Partridge, C. Sanders, J. Katz, J. Tokars, A. Streinu-Cercl, G. Bolokhovets, G. B. Molnar, A. Serban, and A. Mounts for their support and contributions to this manuscript.

**Author contributions**

Laurentiu Zolotusca has coordinated development of this manuscript, acquired all needed data and undertaken descriptive data analyses, has participated in drafting the manuscript, and has approved the current version of the manuscript. Dr. Zolotusca has been the principle point-of-contact in Romania for collaborations with WHO and CDC to establish sentinel SARI surveillance. Pernille Jorgensen is an epidemiologist at the WHO Regional Office for Europe and was the principle data analyst for this manuscript. Pernille also contributed substantially to the writing of all sections of the manuscript. Odette Popovici manages the epidemiologic component of the sentinel surveillance system in Romania, provided analyses of influenza seasonality, manages and updates all of the case-based SARI data, and reports data into the WHO EuroFlu surveillance system on a weekly basis. She has contributed directly to the drafting of the manuscript. Adriana Pistol has provided senior oversight to the sentinel surveillance system in Romania, is responsible for the current expansion of the system, has suggested analyses of case-based data, contributed to the interpretation of findings, and contributed to the drafting of the manuscript. Florin Popovici has been centrally involved in the designing and implementation of SARI.
surveillance in Romania. He is also the IHR point of contact and has particularly enhanced early warning and pandemic monitoring components of SARI surveillance. He has made thoughtful contributions to analyses of these data and has participated in the writing of the manuscript. Caroline Brown runs the Influenza and other Respiratory Disease program at WHO EURO and developed the EuroFlu surveillance system. Dr. Brown participated in validating Romanian data against current EuroFlu data, and in the drafting of the current manuscript. She also created the mechanism that made it possible to provide funding for the establishment and piloting of this sentinel surveillance to Romania. Viorel Alexandrescu supervises the Cantacuzino laboratory where all of the virology work for the current manuscript was undertaken. He contributed to the analyses and interpretation of virologic data, and to the writing of the manuscript with a particular focus on results related to influenza Type and subtype. Alina Ivanciuc also works in the Cantacuzino laboratory, undertakes influenza PCR and culture analyses for the surveillance system, and manages the details of linking laboratory and epidemiologic data for the surveillance system. She has played an integral role in providing laboratory data for this manuscript and has contributed to the analytic interpretation and drafting of the manuscript. Po-Yung Cheng is a statistician at CDC that has provided guidance into these and other analyses of the Romanian sentinel surveillance data. He has contributed to the drafting of the METHODS section and provided revision to the entire manuscript. Diane Gross is an epidemiologist seconded to WHO EURO from CDC. She has provided consultation into the development and expansion of SARI surveillance in Romania and has contributed to all phases of manuscript preparation including analyses and drafting of this version. Marc-Alain Widdowson supervises the International Epidemiology and Research Team and is responsible for all CDC funding for international surveillance activities. He oversaw substantial revision of this manuscript, as well as revisions to the risk factor analyses. He contributed to the introduction and discussion sections as well, and cleared the current draft of this manuscript on behalf of CDC. Joshua Mott as senior author made principle contributions to drafting all sections of this manuscript. He worked closely with Drs. Zolotusca, Pistol and Popovici to conceptualize and implement the SARI surveillance operating procedures in Romania. He also conceptualized the analyses presented in this draft of the manuscript.

References

1. Mereckiene J, Cotter S, D’Ancona F et al. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008–2009. Euro Surveill 2010; 15:pii=19700. Available at http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19700
2. WHO. Global action plan for influenza vaccines. Available at http://www.who.int/influenza_vaccines_plan/objectives/objective2/en/index.html (Accessed 11 February 2013).
3. WHO Regional Office for Europe. WHO Regional Office for Europe guidance for sentinel influenza surveillance in humans Updated–May 2011. Available at www.euro.who.int/__data/assets/pdf_file/0020/90443/E92738.pdf (accessed 10 October 2013).
4. Vaillant L, La Ruche G, Tarantola A et al. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Eurosurveillance 2009; 14:33.
5. Louie J, Acosta M, Jamieson D et al. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med 2010; 362:27–35.
6. Siston A, Rasmussen S, Honein P et al. Pandemic 2009 influenza A (H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303:1517–1525.
7. Louie J, Acosta M, Samuel M et al. A novel risk factor for a novel virus: obesity and 2009 Pandemic Influenza A (H1N1). Clin Infect Dis 2011; 52:301–312.
8. Pelody R, McLean E, Zhao H et al. Pandemic Influenza A (H1N1) 2009 and mortality in the United Kingdom: risk factors for death, April 2009 to March 2010. Eurosurveillance 2010; 15:20.
9. WHO. Background Paper on Influenza Vaccines and Immunization SAGE Working Group, March 26, 2012. Available at http://www.who.int/immunization/sage/meetings/2012/April/1_Background_Paper_Mar26_v13_cleaned.pdf (Accessed 17 January 2013).
10. O’Flanagan D, Cotter S, Mereckiene J. Final report: seasonal influenza vaccination survey in EU/EEA, influenza season 2009-10; VENICE II Consortium; 2011. Available at http://venice.cineca.org/Final_Seasonal_Influenza_Vaccination_Survey_2010.pdf, page 28 (Accessed 22 August 2013).
11. Zolotusca L. Personal communication and transmission of data. National Institute of Public Health, Romania. 21 August, 2013. Available at http://www.insp.gov.ro/crsctb/index.php?option=com_docman&task=cat_view&gid=15&Itemid=13&limitstart=95 (Accessed 10 October 2013).
12. O’Flanagan D, Cotter S, Mereckiene J. Final report: Seasonal influenza vaccination survey in EU/EEA, influenza season 2010-11; VENICE II Consortium; 2012. Available at http://venice.cineca.org/Final_Seasonal_Influenza_2010-11.pdf, page 28 (Accessed 22 August 2013).
13. Jain S, Kamarimoto L, Bramley A et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med 2009; 361:1935–1944.
14. The ANZIC Influenza Investigators. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 361:1925–1934.